Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Sutro Biopharma, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 119
- +2 vs. Q1 2024
- Shares held
- 63.2M
- +9.76M (+18.3%) vs. Q1 2024
- Total value
- $185.1M
- −$116.6M (−38.7%) vs. Q1 2024
- New holders
- 21
- 58 more added
- Sold out
- 19
- 28 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 100 | $545.7M |
| Q1 2026 | 78 | $358.3M |
| Q4 2025 | 63 | $64.8M |
| Q3 2025 | 88 | $46.4M |
| Q2 2025 | 101 | $39.6M |
| Q1 2025 | 113 | $40.0M |
| Q4 2024 | 123 | $117.6M |
| Q3 2024 | 130 | $216.4M |
| Q2 2024 | 119 | $185.1M |
| Q1 2024 | 117 | $301.7M |
| Q4 2023 | 114 | $238.7M |
| Q3 2023 | 109 | $194.3M |
| Q2 2023 | 120 | $251.6M |
| Q1 2023 | 116 | $247.5M |
| Q4 2022 | 119 | $403.7M |
| Q3 2022 | 113 | $279.6M |
| Q2 2022 | 115 | $240.9M |
| Q1 2022 | 114 | $342.2M |
| Q4 2021 | 117 | $593.2M |
| Q3 2021 | 120 | $752.5M |
| Q2 2021 | 124 | $766.7M |
| Q1 2021 | 138 | $1.01B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Sutro Biopharma, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 1,049,372 | $3.07M | 0.00% | +246,637+30.7% | Added |
| Jacobs Levy Equity Management, Inc | 1,050,189 | $3.08M | 0.01% | −19,333−1.8% | Reduced |
| Dimensional Fund Advisors LP | 1,085,281 | $3.18M | 0.00% | −223,603−17.1% | Reduced |
| State Street Corp | 1,565,307 | $4.59M | 0.00% | +368,584+30.8% | Added |
| Acadian Asset Management LLC | 1,574,958 | $4.61M | 0.01% | +370,705+30.8% | Added |
| Citadel Advisors LLC | 1,619,907 | $4.75M | 0.00% | +1,279,166+375.4% | Added |
| Geode Capital Management, LLC | 1,724,941 | $5.05M | 0.00% | +438,625+34.1% | Added |
| Eversept Partners, LP | 1,739,129 | $5.10M | 0.39% | +647,710+59.3% | Added |
| Parkman Healthcare Partners LLC | 1,792,740 | $5.25M | 0.72% | +2,689+0.2% | Added |
| Baillie Gifford & Co | 1,848,751 | $5.42M | 0.00% | +1,845+0.1% | Added |
| Adage Capital Partners GP, L.L.C. | 2,000,000 | $5.86M | 0.01% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 2,023,683 | $5.93M | 0.62% | +21,956+1.1% | Added |
| Samsara BioCapital, LLC | 2,196,814 | $6.44M | 1.35% | +521,235+31.1% | Added |
| MPM Oncology Impact Management LP | 3,043,346 | $8.92M | 1.39% | −1,053,273−25.7% | Reduced |
| Vanguard Group Inc | 3,555,340 | $10.4M | 0.00% | +532,550+17.6% | Added |
| Millennium Management LLC | 4,361,893 | $12.8M | 0.01% | −374,070−7.9% | Reduced |
| Point72 Asset Management, L.P. | 4,447,634 | $13.0M | 0.04% | +4,186,938+1,606.1% | Added |
| BlackRock Inc. | 6,910,730 | $20.2M | 0.00% | +1,208,825+21.2% | Added |
| Suvretta Capital Management, LLC | 7,708,690 | $22.6M | 0.92% | +1,930,502+33.4% | Added |
| Candriam Luxembourg S.C.A. | 0 | $0 | 0.00% | −440,422−100.0% | Sold out |
| Propel Bio Management, LLC | 0 | $0 | 0.00% | −195,000−100.0% | Sold out |
| Simplify Asset Management Inc. | 0 | $0 | 0.00% | −120,000−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −111,197−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −69,678−100.0% | Sold out |
| Lighthouse Investment Partners, LLC | 0 | $0 | 0.00% | −66,585−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −63,157−100.0% | Sold out |
| Chase Investment Counsel Corp | 0 | $0 | 0.00% | −57,700−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −44,019−100.0% | Sold out |
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −30,947−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −30,017−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −23,291−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −16,925−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −16,386−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,057−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −2,100−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −1,632−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −285−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |